Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease
The authors declare that they do not have any conflict of interest to disclose in terms of funding for this manuscript (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 12, 2023 Category: Gastroenterology Authors: Junhong Chen, Hao Zhou, Kai Liu Tags: Letter to the Editor Source Type: research
Reply letter to the letter to the editor entitled: “5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?”
We thank Dr Fernandez-Garza for the interest in our work and for his comments on the statistical analysis. He underlines that our intention-to-treat analysis (ITT) did not include all planned randomized patients (30 per group) and that we do not explain why [1]. We would like to clarify this point. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 12, 2023 Category: Gastroenterology Authors: Ranka Vukotic, Roberto Di Donato, Jaime Bosch, Pietro Andreone Tags: Letter to the Editor Source Type: research
Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study
We read with great interest the study by Roca-Fernandez A et al. which revealed the associations of early liver disease on iron-corrected T1(cT1) mapping with the risk of cardiovascular disease using 33,616 participants from the UK Biobank (UKBB).[1] However, conventional observational studies are susceptible to potential bias such as unmeasured confounders and reverse causality, the result can hardly be interpreted as causal associations. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 12, 2023 Category: Gastroenterology Authors: Chiyu He, Di Lu, Shusen Zheng, Xiao Xu Tags: Letter to the Editor Source Type: research
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
In patients with cirrhosis, transjugular intrahepatic portosystemic shunt (TIPS) is indicated for the prophylaxis of variceal re-bleeding and treatment of refractory ascites. Overt hepatic encephalopathy (OHE) is a major complication after TIPS, given its high incidence and possibility of refractoriness to medical treatment. Nevertheless, the impact of post-TIPS OHE on mortality has not been investigated in a large population. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 12, 2023 Category: Gastroenterology Authors: Silvia Nardelli, Oliviero Riggio, Fabio Marra, Stefania Gioia, Dario Saltini, Daniele Bellafante, Valentina Adotti, Tomas Guasconi, Lorenzo Ridola, Martina Rosi, C. Caporali, Fabrizio Fanelli, Davide Roccarina, Marcello Bianchini, Federica Indulti, Alessa Tags: Research Article Source Type: research
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study
Chronic liver disease (CLD) causes 1.8% of all deaths in Europe, many of them from liver cancer. We estimated the impact of several policy interventions the Netherlands, and Romania. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 11, 2023 Category: Gastroenterology Authors: Lise Retat, Laura Webber, Peter Jepsen, Alexander Martin, Helena Cortez- Pinto, Jeffrey V. Lazarus, Francesco Negro, Markiyan Mitchyn, John Guzek, Joshua Card-Gowers, Hannah Graff, Pierre Nahon, Nick Sheron, Shira Zelber Sagi, Maria Buti Tags: Research Article Source Type: research
Hepatic prohibitin 1 and methionine adenosyltransferase α1 defend against primary and secondary liver cancer metastasis
Liver is a common site of cancer metastasis (a.k.a. secondary liver cancer, most commonly from colorectal cancer (CRC)) and primary liver cancers that have metastasized have poor prognosis. The underlying mechanisms of how the liver defends against these processes are largely unknown. Prohibitin 1 (PHB1) and methionine adenosyltransferase 1A (MAT1A) are highly expressed in the liver. They positively regulate each other and their deletion results in primary liver cancer. Here we investigated their roles in primary and secondary liver cancer metastasis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 10, 2023 Category: Gastroenterology Authors: Wei Fan, DuoYao Cao, Bing Yang, Jiaohong Wang, Xiaomo Li, Diana Kitka, Tony W.H. Li, Sungyong You, Stephen Shiao, Alexandra Gangi, Edwin Posadas, Dolores Di Vizio, Maria Lauda Tomasi, Ekihiro Seki, Jos é M. Mato, Heping Yang, Shelly C. Lu Tags: Research Article Source Type: research
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease
In Wilson Disease (WD), copper accumulates in the liver and brain causing disease. Bis-choline tetrathiomolybdate (TTM) is a potent copper chelator that may have a lower risk of inducing paradoxical neurological worsening than conventional therapy for neurologic WD. To better understand the mode of action of TTM, we investigated the effects of TTM on copper absorption and biliary excretion. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 9, 2023 Category: Gastroenterology Authors: Frederik Teicher Kirk, Ditte Emilie Munk, Eugene Scott Swenson, Adam M. Quicquaro, Mikkel Holm Vendelbo, Agnete Larsen, Michael L. Schilsky, Peter Ott, Thomas Damgaard Sandahl Tags: Research Article Source Type: research
Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis
Liver fibrosis, a leading cause of cirrhosis and liver cancer, is the advanced stage of non-alcoholic fatty liver disease (NAFLD). There is an urgent need for antifibrotic therapeutics targeting hepatic fibrosis as no treatments are currently approved.1 Recently, Jiwoon et al. developed a human pluripotent stem cell-derived multicellular liver culture and revealed that the IL-6/STAT3 signaling pathway may dictate hepatic stellate cell (HSC) activation and NAFLD progression.2 A mouse model study by Dai-Min et al. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 8, 2023 Category: Gastroenterology Authors: Hongjun Xiao, Dan Niu, Bo Zhang Tags: Letter to the Editor Source Type: research
Combined inhibition of Stat3 and Periostin synergistically protects mice against liver fibrosis.
Study concept and design: Hongjun Xiao, Bo Zhang. Methodology:Hongjun Xiao, Bo Zhang. Acquisition of data: Hongjun Xiao, Dan Niu. Analysis and interpretation of data: Hongjun Xiao, Dan Niu, Bo Zhang. Drafting of the manuscript: Hongjun Xiao. Critical revision of the manuscript: Bo Zhang. Funding acquisition: Bo Zhang. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 8, 2023 Category: Gastroenterology Authors: Xiao Hongjun, Niu Dan, Zhang Bo Tags: Letter to the Editor Source Type: research
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials
Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction-associated steatohepatitis (MASH; MASH with metabolic dysfunction-associated steatotic liver disease score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® te chnology designed to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for opti...
Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Tags: Research Article Source Type: research
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction –associated steatohepatitis clinical trials
Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction–associated steatohepatitis (MASH; MASH with non-alcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® technology des igned to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for optimal selectio...
Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Source Type: research
Comprehensive gene profiling of the metabolic landscape of humanized livers in mice
The human liver transcriptome is complex and highly dynamic, e.g., one gene may produce multiple distinct transcripts, each with distinct posttranscriptional modifications. Direct knowledge of the transcriptome dynamics, however, is largely obscured by the inaccessibility of human liver to treatments and the insufficient annotation of the human liver transcriptome at transcript and RNA modifications levels. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 2, 2023 Category: Gastroenterology Authors: Chengfei Jiang, Ping Li, Yonghe Ma, Nao Yoneda, Kenji Kawai, Shotaro Uehara, Yasuyuki Ohnishi, Hiroshi Suemizu, Haiming Cao Tags: Research Article Source Type: research
MASLD emerging from the fog of fatty liver
The recent changes in the nomenclature of what has been defined for more than two decades as “non-alcoholic fatty liver disease” (NAFLD) derive from the lack of a clear pathophysiological framing and a longstanding uneasiness in using terms such as “alcoholic” and “fatty” for the hepatic manifestation of a systemic metabolic derangement mostly characterized by cardiovascular out comes. Along these lines, the term “non-alcoholic” did not accurately capture the aetiology of the disease. For instance, individuals with risk factors for NAFLD, such as type 2 diabetes (T2DM), who consume more alcohol than the rel...
Source: Journal of Hepatology - November 30, 2023 Category: Gastroenterology Authors: Giulio Marchesini, Roberto Vettor, Massimo Pinzani Tags: Editorial Source Type: research
Corrigendum to “Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation” [J Hepatol (2023) 645–656]
It has come to our attention that there was an error in Fig. 4G (left panel) of our manuscript. The size of the protein Flag-3ABC was incorrectly labelled as ‘75 kDa’ instead of its correct size ‘38 kDa’. This is corrected in the updated figure below. We apologise for any inconvenience caused. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 30, 2023 Category: Gastroenterology Authors: Ombretta Colasanti, Rani Burm, Hao-En Huang, Tobias Riedl, Jannik Traut, Nadine Gillich, Teng-Feng Li, Laura Corneillie, Suzanne Faure-Dupuy, Oliver Gr ünvogel, Danijela Heide, Ji-Young Lee, Cong Si Tran, Uta Merle, Maria Chironna, Florian F.W. Vondran, Tags: Corrigendum Source Type: research
Suboptimal hydration status increases the risk of incident MASLD: A pediatric cohort study
We have thoroughly reviewed the article written by Rinella et al.,1 which presented the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD). Following screening for hepatic steatosis, the assessment of MASLD involved several key parameters, which are closely related to metabolic function including BMI, waist circumference, bloo d pressure, and blood biochemistry test indexes.1 These parameters are widely used in epidemiological studies pertaining to child and adolescent health. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Menglong Li, Huidi Xiao, Yeerlin Asihaer, Yingfeng Wu, Yifei Hu Tags: Letter to the Editor Source Type: research
